Pancreatic Islet Mass in Pregnancy in Type 1 Diabetes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00548522
Recruitment Status : Terminated (Difficulty in finding staff to help with study)
First Posted : October 24, 2007
Last Update Posted : May 22, 2014
Information provided by (Responsible Party):
Edmond A Ryan, University of Alberta

Brief Summary:
Type 1 diabetic women have a decrease in insulin requirements during early pregnancy. Preliminary evidence suggests this decrease may be secondary to the regeneration of pancreatic B-cells during pregnancy During the second and third trimesters, insulin requirements in Type 1 diabetic women progressively increase until approximately 36 weeks gestation at which time there is a plateau, and frequently, a drop in insulin requirements. We hypothesize that there is regeneration of pancreatic islet cell mass in Type 1 diabetic women during pregnancy. In a cross-sectional study, we will use the acute insulin c-peptide response to arginine to determine if pancreatic islet mass increases at 12 and 36 weeks gestation. Type 1 diabetic women who are not pregnant, who are at 12 and 36 weeks gestation, and who are 6 weeks post-partum will undergo an intravenous arginine tolerance test following an overnight fast. If we find that there is regeneration of beta cells it opens the possibility that therapy may be directed to the same end for people with Type 1 diabetes.

Condition or disease
Type 1 Diabetes Pregnancy

  Show Detailed Description

Study Type : Observational
Actual Enrollment : 12 participants
Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Pancreatic Islet Mass in Pregnancy - Pilot Study
Study Start Date : August 2007
Actual Primary Completion Date : December 2013
Actual Study Completion Date : December 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Diabetes Type 1

Pregnant (12 - 16 wks gestation) women with Type 1 diabetes
Pregnant women (34-38 wks gestation) with Type 1 diabetes
Post partum women with Type 1 diabetes
Non pregnant women with Type 1 diabetes

Primary Outcome Measures :
  1. The documentation of Cpeptide in women with type 1 diabetes who are pregnant [ Time Frame: 1 year ]

Biospecimen Retention:   Samples Without DNA
Plasma Samples kept for batching of antibody assays

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 40 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant women with Type 1 diabetes

Inclusion Criteria:

  • Signed informed consent
  • Females with Type 1 diabetes for at least 5 years
  • Diabetes onset < 21 years
  • Lean at diabetes onset
  • Insulin required from diagnosis
  • Willing to undergo intravenous arginine tolerance tests

Exclusion Criteria:

  • Inability to provide informed consent
  • Any medical condition that would preclude safe conduct of the intravenous arginine
  • A family history which includes three generations of family members with the diagnosis of diabetes mellitus
  • Women with elevated serum creatinine as arginine is excreted by the kidneys.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00548522

Canada, Alberta
University of Alberta Hospital
Edmonton, Alberta, Canada, T6G 2B7
University of Alberta
Edmonton, Alberta, Canada, T6G 2S2
Sponsors and Collaborators
University of Alberta
Principal Investigator: Edmond A Ryan, MD University of Alberta

Responsible Party: Edmond A Ryan, Professor, University of Alberta Identifier: NCT00548522     History of Changes
Other Study ID Numbers: UAHREB4503
First Posted: October 24, 2007    Key Record Dates
Last Update Posted: May 22, 2014
Last Verified: May 2014

Keywords provided by Edmond A Ryan, University of Alberta:
Type 1 Diabetes
Islet Mass

Additional relevant MeSH terms:
Diabetes Mellitus, Type 1
Diabetes Mellitus
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Autoimmune Diseases
Immune System Diseases